SelectScience
Join Free
NewsLife Sciences

Dual Mechanism Inhibitor Against Chronic Lymphocytic Leukemia Announced

Inflection Biosciences Ltd
19 Jul 2018
Han Yin
Administrator / Office Personnel

Industry news

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer has announced the publication of preclinical data showing the company’s dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia (CLL).

The preclinical research was conducted in collaboration with Dr. Oliver Giles Best of the Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Australia, and a member of the CLL Australian Research Consortium (CLLARC), Sydney, Australia.

Despite significant advances in treatment, CLL remains an incurable disease. Given the growing body of evidence suggesting CLL cells may adapt to, survive and even proliferate under hypoxic conditions of the tumor microenvironment, new treatment options which are effective under these conditions are required.

The published results show that IBL‐202 is cytotoxic against CLL cells under in vitro conditions that mimic the hypoxic tumor microenvironment. The publication also demonstrates the significant effects of IBL‐202 on CD49d and CXCR4 gene expression and on the migration, cycling and proliferation of CLL cells, suggesting the drug may significantly impair the migratory and proliferative capacity of the leukemic cells.

Dr. Best, lead author on the publication, commented: “Collectively, this data demonstrates that dual inhibition of the PIM and PI3 kinases by IBL‐202 may be an effective strategy for targeting CLL cells, particularly within the environmental niches known to confer drug‐resistance.”

Receive more news on cancer drug discoveries, join our Drug Discovery & Development Community.

Links

Inflection Biosciences LtdCompany website

Tags

ProteomicsProteomics is the systemic bioinformatics study of proteins and amino acids, including their structure, size, function and identification. Tools used in proteomics include chromatography, blotting and gels, protein arrays, mass spectrometry and ELISA and associated analysis software. Analyzers and proteomic systems should be sensitive, high resolution, fast and may be automated for high-throughput.Data AnalysisData analysis hardware and software is available to make data processing straight-forward yet powerful. Data software can be used for math and stats, technical graphing and image analysis. In addition, software is available for specific data analysis of electrophoresis, densitometry, ELISA and DNA sequencing.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.Cell AnalysisThe analysis of cells allows researchers to understand the factors which contribute to cell health and function. These influencing processes can then be predicted and altered, leading to the development of medication and disease treatments.InhibitorsHypoxiaTumorsTumor research focuses on understanding abnormal cell growth that leads to cancer. Identifying biomarkers, studying tumor microenvironments, and developing targeted therapies are critical for advancing cancer treatment. Early detection and personalized treatment options are key to improving outcomes for patients. Browse our peer-reviewed product directory to explore tools for tumor research, diagnostics, and cancer therapies; compare products, read customer reviews, and get pricing directly from manufacturers.Drug Discovery & Development ScreeningCancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles

Dual Mechanism Inhibitor Against Chronic Lymphocytic Leukemia Announced